



**AMDL Contact:**  
Kristine Szarkowitz  
Director-Investor Relations  
[kszarkowitz@radient-pharma.com](mailto:kszarkowitz@radient-pharma.com)  
(Tel :) 206.310.5323

**FOR IMMEDIATE RELEASE**

## **RADIANT PHARMACEUTICALS SIGNS RESEARCH COLLABORATION AGREEMENT WITH CETECANCER**

*Research to validate Company's Onko-Sure™ in vitro diagnostic cancer test as an early detection and prevention test for lung cancer*

---

**(TUSTIN, CA) October 15, 2009/PRNewswire** –Radiant Pharmaceuticals Corporation (NYSE - AMEX: [RPC](#) - [News](#)), a US-based pharmaceutical company, announced today it has entered into a collaboration agreement through its wholly-owned subsidiary AMDL Diagnostics, Inc. (ADI) with CeTeCancer – a Chilean-based research laboratory, to validate the effectiveness of ADI's Onko-Sure™ *in vitro* diagnostic (IVD) cancer test as an early detection and prevention test for lung cancer.

ADI and CeTeCancer will collaborate on a research project entitled “*Early Detection and Prevention of Lung Cancer Using Recent Advances in Genomics and Imagen*” using the Onko-Sure™ cancer test kit, among others, for the detection of lung cancer. The purpose of the research project is to identify an effective early-detection and prevention program for lung cancer. CeTeCancer will analyze samples and perform all of the clinical testing. The research project is supported in part by INNOVA CORFO and will run for 24 months with final results anticipated to be published in early 2011. CeTeCancer, Chile, in collaboration with BCCA, and PMIlabs from Canada is introducing in Chile three new technologies for lung cancer early detection: Induced Sputum Analysis by Quantitative Automatic Cytology, Bronchoscopy Autofluorescent and Comparative Genome Hybridization.

“We are delighted to enter into this partnership with a highly innovative scientific group working to detect and potentially prevent the deadly and worldwide spread of lung cancer,” said Mr. Douglas MacLellan, Chairman and CEO of Radiant Pharmaceuticals. “The expected results of this project should significantly accelerate the international commercialization of Onko-Sure™ and bring Radiant Pharmaceuticals one step closer to securing its leadership position in the cancer IVD test market.”

According to the World Health Organization (WHO), more than 1.2 million cases of lung cancer are diagnosed each year establishing it as the #1 deadliest cancer worldwide. Lung cancer causes more deaths globally than colon, prostate and breast cancer combined and the disease accounts for the largest number of new cancers cases and deaths annually, with a single patient dying from the disease every 30 seconds. In 2008, approximately 1.52 million new cases of lung

cancer were diagnosed worldwide, with 1.31 million people dying from the disease (WHO), and in the United States, an estimated 161,840 deaths, accounting for 29 percent of all cancer deaths, occurred in 2008, according to the American Cancer Society (ACS). Through its lung cancer research collaboration with CeTeCancer, Radient Pharmaceuticals is working to improve detection and prevention of the disease using Onko-Sure.

In the USA Onko-Sure has been cleared for the monitoring of colorectal cancer by the US FDA (July 2008). ADI continues to expand its commercialization of Onko-Sure™ in select international markets. For additional information on Radient Pharmaceuticals, ADI and its portfolio of products visit the Company's corporate website at [www.Radient-Pharma.com](http://www.Radient-Pharma.com). For Investor Relations information contact Kristine Szarkowitz at [kszarkowitz@Radient-Pharma.com](mailto:kszarkowitz@Radient-Pharma.com) or 1.206.310.5323.

**About Radient Pharmaceuticals:**

Headquartered in Tustin, California, Radient Pharmaceuticals Corporation is an integrated pharmaceutical company devoted to the research, development, manufacturing, and marketing of diagnostic, and premium skin care products.

**Forward Looking Statements:**

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward-looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Corporation, except for the historical information contained herein, the matters discussed in this document are forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements.

---

---